# Evaluation of commercial anti-SARS-CoV-2 antibody assays and comparison of standardized titers in vaccinated healthcare workers.

3

Kahina Saker<sup>1</sup>, Vanessa Escuret<sup>1,4</sup>, Virginie Pitiot<sup>2</sup>, Amélie Massardier-Pilonchéry<sup>2</sup>. Stéphane 4 5 Paul<sup>3</sup>, Bouchra Mokdad<sup>1</sup>, Carole Langlois-Jacques<sup>5</sup>, Muriel Rabilloud<sup>5</sup>, David Goncalves<sup>6</sup>, 6 Nicole Fabien<sup>6</sup>, Nicolas Guibert<sup>2</sup>, Jean-Baptiste Fassier<sup>2</sup>, Antonin Bal<sup>1</sup>, Sophie Trouillet-Assant<sup>1,4</sup>, Mary-Anne Trabaud<sup>1</sup>. 7 8 9 <sup>1</sup>Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre 10 National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, IAI, 11 Centre de Biologie Nord, Groupement Hospitalier Nord, F-69317, Lyon Cedex 04, France 12 <sup>2</sup>Occupational Health and Medicine Department, Hospices Civils de Lyon, Lyon, France 13 <sup>3</sup>Laboratory of Immunology and Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, 14 University Hospital of Saint-Etienne, F-42055, Saint-Etienne cedex 2, France 15 <sup>4</sup>CIRI- International Center of Research in Infectiology, INSERM U1111, CNRS UMR5308, 16 ENS Lyon, Claude Bernard Lyon 1 University, F-69008, Lyon, France. 17 <sup>5</sup>CNRS, UMR 5558, University of Lyon, Laboratoire de Biométrie et Biologie Evolutive, 18 Equipe Biostatistique-Santé, F-69100, Villeurbanne, France 19 <sup>6</sup>Immunology Department, Lyon Sud Hospital, Hospices Civils de Lyon, F-69495, Pierre-20 Bénite cedex, France 21 **Corresponding author** 22 Mary-Anne Trabaud, mary-anne.trabaud01@chu-lyon.fr 23 **Running title:** Comparison of SARS-CoV-2 antibody titers after vaccination 24 Keywords: SARS-CoV-2 antibodies; quantification; commercial assays; standardized titers; 25 vaccination; health care workers

## 26 Abstract

With the availability of vaccines, commercial assays detecting anti-SARS-CoV-2 antibodies (Ab) evolved towards quantitative assays directed to the spike glycoprotein or its receptor binding domain (RBD). The main objective of the present study was to compare the Ab titers obtained with quantitative commercial binding Ab assays, after 1 dose (convalescent individuals) or 2 doses (naïve individuals) of vaccine, in healthcare workers (HCW).

Antibody titers were measured in 255 sera (from 150 HCW) with 5 quantitative immunoassays (Abbott RBD IgG II quant, bioMérieux RBD IgG, DiaSorin Trimeric spike IgG, Siemens Healthineers RBD IgG, Wantai RBD IgG). One qualitative total antibody anti RBD detection assay (Wantai) was used to detect previous infection before vaccination. The results are presented in binding Ab units (BAU)/mL after application, when possible, of a conversion factor provided by the manufacturers and established from a World Health Organization (WHO) internal standard.

There was a 100% seroconversion with all assays evaluated after two doses of vaccine. With assays allowing BAU/ml correction, Ab titers were correlated (Pearson correlation coefficient,  $\rho$ , range: 0.85-0.94). The titer differences varied by a mean of 10.6% between Siemens and bioMérieux assays to 60.9% between Abbott and DiaSorin assays. These results underline the importance of BAU conversion for the comparison of Ab titer obtained with the different quantitative assays. However, significant differences persist, notably, between kits detecting Ab against the different antigens.

46 A true standardization of the assays would be to include the International Standard in the
47 calibration of each assays to express the results in IU/mL.

## 49 Introduction

50 Since the end of 2020, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) 51 vaccines have become available worldwide with the aim of achieving herd immunity to 52 control the pandemic. Vaccine immunity involves both cellular and humoral pathways. 53 Cellular immunity is not easy to assess on a large scale, as is the neutralizing humoral 54 response owing to requirement for a biosafety level 3 (BSL3) containment laboratory. The 55 evaluation of vaccine effectiveness therefore mainly relies on high throughput serological 56 tests to assess individual humoral immunity as well as monitoring SARS-CoV-2 57 seroprevalence (1).

58 To effectively utilize measurements of binding antibodies (Ab) as indicators of vaccine 59 effectiveness, several conditions must be met. First, binding Ab assays should be quantitative; 60 second, titers should be consistent between different assays; third, binding Ab titers should 61 correlate with neutralizing Ab titers; fourth, the minimum binding Ab titer associated with 62 virus neutralization must be found; and fifth, the association between neutralizing Ab and 63 vaccine protection must be demonstrated. It can be considered that the first and fifth 64 conditions have been met given that commercial tests for the quantitative detection of binding 65 Ab have been developed (2-8), and that the role of neutralizing Ab in the infection protection 66 have been demonstrated in animals and humans (9-12). This is not the case for the other 67 conditions; in particular, the second point is of importance for widespread evaluation of 68 vaccines, but until now, Ab titers were often expressed as an index or unit with regard to an 69 internal standard that differs between manufacturers. Recently, the World Health 70 Organization (WHO) has developed an international standard (13) against which each 71 supplier can standardize their assay, allowing comparability of titers between kits. The present 72 study was conducted to evaluate the performance of commercial antibody assays in detecting 73 vaccination-associated anti-SARS-CoV-2 Ab seroconversion; the main objective was to

compare Ab titers from quantitative assays after conversion of titers with the conversion
factor obtained using the WHO standard and provided by each manufacturer.

76

## 77 Materials and Methods

#### 78 Antibody binding assays

79 Six CE-marked Ab binding assays, validated by each manufacturer, were investigated 80 according to the protocol recommended by each manufacturer (the characteristics of the 81 assays are summarized in Table 1). Five were quantitative: Siemens Healthineers (Erlangen, 82 Germany) Atellica® IM SARS-CoV-2 IgG (sCOVG; used in routine in our laboratory), 83 DiaSorin (Saluggia, Italy) Liaison® SARS-CoV-2 TrimericS IgG, bioMérieux (Marcy 84 l'Etoile, France) Vidas® SARS-CoV-2 IgG (clinically used for confirmation if necessary), 85 Abbott (Abbott park, II, USA) Architect SARS-CoV2 IgG II Quant, and Wantai (Beijing, 86 China) SARS-CoV-2 IgG assays. The Wantai SARS-CoV-2 total antibody assay is qualitative 87 and was selected to detect a previous infection before vaccination based on its better 88 sensitivity in infected individuals compared to other commercial qualitative assays we have 89 evaluated in a previous study (14). The First International Standard developed by the WHO 90 (National Institute for Biological Standards and Control code: 20/136) corresponds to 91 lyophilized pooled plasma from patients who had been infected with SARS-CoV-2; after 92 reconstitution, the solution contains 1000 binding antibody units (BAU) per mL (13).

For conversion of titers obtained using the quantitative assays, the concentrations expressed in arbitrary units per mL, or index according to the assay (Table 1), were converted to BAU/mL using the conversion factors provided a posteriori (not included in the main procedure but as a separate document – either by electronic or postal mail) by the manufacturer (with the exception of the Wantai SARS-CoV-2 IgG assay for which the conversion factor was not available and presented here only to compare the positivity rate between assays); these were

99 21.8 for the Siemens assay, 2.6 for the DiaSorin assay, 20.33 for the bioMérieux assay, and 100 0.142 for the Abbott assay (considering that 1 BAU/mL = conversion factor x AU/mL or 101 index). Samples with results above the upper limit of quantification were tested again after 102 dilution (1/5 when above 3270 BAU/mL for the Siemens assay, 1/20 when above 2080 103 BAU/mL for the DiaSorin assay, 1/20 when above 18 index for the bioMérieux assay, and 1/2 104 when above 5680 BAU/mL for the Abbott assay).

## 105 Samples from the study population

106 A prospective longitudinal cohort study was conducted at the laboratory associated with the 107 national reference center for respiratory viruses (University Hospital of Lyon, France). 108 Healthcare workers, excluding pregnant women (HCW; n=150) who were scheduled to 109 receive 2 doses of Pfizer BioNtech vaccine (n=94; BNT162b2/BNT162b2; 78% female; 110 median age 48.5 [range: 21-76] vears) or 1 dose of AstraZeneca vaccine followed by 1 dose 111 of Pfizer BioNtech vaccine (n=56; ChAdOx1/BNT162b2; 70% female; median age 33.5 112 [range: 21-55] years) were included. Blood samples were collected i) before the first dose of 113 vaccine, ii) before the second injection of vaccine corresponding to 4 weeks after the first 114 dose for participants vaccinated with 2 doses of Pfizer BioNtech vaccine (median delay of 28 115 [range: 21-37] days) or 12 weeks for those vaccinated with the AstraZeneca vaccine (median 116 delay of 85 [range: 84-97] days), and iii) 4 weeks after the full vaccination. The pre-117 vaccination blood sample was used to document a previous SARS-CoV-2 infection. Among 118 the participants, 26 who were previously infected with SARS-CoV-2 (convalescent group; 119 17.4%) had only one vaccine injection (Pfizer BioNtech, n=15 or Astra Zeneca, n=11); for 120 these the second sample was omitted. Three participants were infected with SARS-CoV-2 121 between the 2 doses. Serum samples were prepared from 5 mL of whole blood collected in BD Vacutainer® Serum Separator Tubes II Advance (Beckon Dickinson Diagnostics). After 122 123 collection, tubes were shaken gently and serum allowed to clot for a minimum 30 min at room

temperature to obtain total coagulation, followed by centrifugation at 2,000 g for 10 min.

- 125 Serum removed from gel was stored at -80°C until serological assays were performed.
- 126 Written informed consent was obtained from all participants; ethics approval was obtained
- 127 from the regional review board for biomedical research in April 2020 (Comité de Protection
- 128 des Personnes Sud Méditerranée I, Marseille, France; ID RCB 2020-A00932-37), and the
- 129 study was registered on ClinicalTrials.gov (NCT04341142).

#### 130 Statistical analyses

131 Results were expressed by the median and interquartile range [IQR]. Paired comparison 132 between assays was performed using the Wilcoxon test. The correlation between 133 concentrations obtained by each assay was investigated using Pearson correlation coefficients 134 and 95% confidence interval (CI). To estimate proportional bias between two methods, 135 Passing and Bablok regression was used and the regression line equation was calculated from 136 the two data sets. The Bland-Altman method was used to measure the mean difference and 137 95% limit of agreement between log-transformed concentrations obtained with each assay. 138 Statistical analyses were conducted using GraphPad Prism® software (version 8; GraphPad 139 software, La Jolla, CA, USA). A p-value <0.05 was considered statistically significant.

140

# 141 **Results**

In the first part of the study, the performances of the six assays were compared to verify whether the ability to detect anti-SARS-CoV-2 antibodies of the Wantai total Ab assay, previously found as the most sensitive post-infection compared to other commercial qualitative assays (14), was similar after vaccination, and whether the sensitivity of qualitative and quantitative assays were also similar. The sera collected from patients scheduled to receive only Pfizer BioNtech vaccine (two doses 3 to 4 weeks apart, n=79) were used for this

evaluation. Four weeks after the first injection, the proportion of positive samples was over 90% for all assays except the Wantai assay detecting total antibodies (86.1%). Only one sample was negative with all assays. Six samples were negative with only one assay (5 with the Wantai total Ig assay, 1 with the Wantai IgG assay). Four samples were negative with 3 to 5 assays. In all of these cases the signals from positive assays were low. Four weeks after the second injection anti SARS CoV-2 antibodies were detected for all participants with all the assays (Table 1).

155 The second part of this study was to compare Ab titers after BAU/mL conversion; for this, 156 only the assays adapted or developed for the quantification of Ab were tested. The Siemens, 157 DiaSorin, bioMérieux and Abbott assays were compared using sera samples collected before 158 the second injection of vaccine and those collected after full vaccination, and for which assays 159 gave a positive quantitative result (255 samples). The median [IQR] values obtained were 160 744.9 [108.1; 2482] BAU/mL for the Siemens, 1240 [262.6; 3370] BAU/mL for the DiaSorin, 161 951.4 [142.5; 2314] BAU/mL for the bioMérieux, and 768.9 [100.8; 1916] BAU/mL for the 162 Abbott assays; there was a significant difference in median titers between DiaSorin and 163 Siemens (p < 0.0001), between DiaSorin and bioMérieux (p < 0.0001), as well as between 164 Abbott and each assay (p<0.0001). The difference in median titers between Siemens and 165 bioMérieux assays was not significant (Figure 1). There was a strong correlation between 166 assays (Table 2).

167 The slopes of the Passing and Bablock regression curves were calculated by pairwise 168 comparison of each assay. The deviation from the perfect correlation was significantly greater 169 between DiaSorin and each of the other assays than between each of these other assays. In 170 most cases, there was a proportional difference between assays (Figure 2). In particular, 171 DiaSorin assay values reached higher levels than the other methods; 11 samples had a value

above 10,000 BAU/ml while only three reached this threshold with the Siemens assay and

173 none with the BioMérieux and Abbott assays.

According to the Bland-Altman method there was a mean [95%CI] difference in titers expressed as BAU concentrations of 50.9% [46.4%; 55.3%] between the Siemens and DiaSorin assays, 40.4% [35.5%; 45.3%] between bioMérieux and DiaSorin assays, 60.9% [55.9%; 66%] between Abbott and DiaSorin assays, 10.6% [5.8%; 15.4%] between Siemens and bioMérieux assays, 12.1% [16.2%; 8%] between Siemens and Abbott assays, and 22.3% [17.5%; 27.1%] between Abbott and bioMérieux assays (Figure 3).

180

### 181 Discussion

182 In the present cohort of vaccinated HCW, the performance of qualitative serological assays, 183 developed for diagnostic purposes at the beginning of the pandemic, as well as those adapted 184 or developed when the vaccine became available, were similar. However, assays developed 185 for detecting a past infection are not useful to monitor vaccination effectiveness since they are 186 not quantitative or could not be compared to others. The more important finding of the 187 present study was that the quantitative assays, whose results could be standardized to 188 BAU/ml, produce results that are correlated to each other. The Ab titers obtained with the 189 DiaSorin assay, although correlated with those of the other assays, remained higher after 190 conversion using the WHO standard. This may be related to difference in the antigens 191 targeted, as the DiaSorin assay is the only one evaluated in this study, to use the trimeric spike 192 protein (2). The WHO standard was obtained from the plasma of convalescent patients (13) 193 and must therefore contain antibodies against numerous epitopes, thus the DiaSorin assay is 194 probably capable of reacting with more antibodies than assays detecting only antibodies 195 specific for RBD.

196 There are currently very few reports that have examined Ab binding assays with the use of the 197 WHO standard (3, 7). Perkman et al. (7) compared four assays detecting binding Ab, 198 including the Liaison anti SARS-CoV-2 trimeric S IgG from DiaSorin and the Architect anti 199 SARS-CoV-2 RBD IgG from Abbott, used in the present study. In vaccinated individuals, 200 after the first dose of vaccine, titers varied significantly between the assays, but they indicated 201 that the recalculation in BAU/ml with the conversion factor given by the manufacturer did not 202 solve error problems between tests. However, the assays compared were more different in 203 their format than those investigated herein: total anti-RBD Ig versus anti-RBD IgG, anti-204 monomeric spike IgG or anti-trimeric spike IgG. Interestingly, comparison of Abbott and 205 DiaSorin assays found, as was the case herein, higher titers for the DiaSorin assay. Later, 206 Bradley et al. (3) performed linear regressions from sample dilutions of the WHO standard to 207 determine a detection limit in international units (IU) per ml for each test; the authors 208 confirmed the linearity of the Abbott anti-SARS-CoV-2 IgG II Quant assay over the 209 analytical measurement interval but the conversion factor found seemed to be higher than 210 indicated by the manufacturer (1 IU/ml gave 6,1 arbitrary units/ml while Abbott indicated that 211 1 IU correspond to 7.1 arbitrary units). Taken together, these data suggest that there are 212 remaining differences between assays after conversion in BAU/ml and that this could be due 213 to the incorrect adjustment of the correction factor by the manufacturers. The next step for a 214 true harmonization would therefore be to use the international standard to calibrate each assay 215 instead of applying a conversion factor to a result obtained with an assay previously calibrated 216 with an internal standard (15).

A limitation of this study is the absence of specificity analysis. However, assay specificity analyses have been performed by manufacturers and independent groups (2, 4-6) showing specificity  $\geq$ 99% for all the quantitative assays. A point that may be also considered as a limitation is the choice to use the conversion factors obtained by the manufacturers without

221 testing the WHO standard ourselves; but the aim of the present study was to evaluate these 222 assays under the conditions offered by the manufacturers to all their customers. In addition, 223 not all commercial quantitative anti-SARS-CoV-2 Ab assays were evaluated, limiting the 224 scope of the conclusions. Furthermore, neutralizing Ab were not investigated that could have 225 helped determine whether anti-RBD or anti-spike assays are the most correlated with virus 226 neutralization. However, before investigating this, harmonization of neutralizing Ab titers is 227 also necessary to determine a common threshold from which vaccine protection could be 228 predicted, allowing then to find the corresponding threshold with high throughput binding Ab 229 assays. A study comparing different cell-based assays (with either live or pseudotyped 230 viruses) to measure neutralization in vitro is rather reassuring, although differences were 231 found according to the viruses used for pseudotyping (16). However, comparison of cell-232 based assays with surrogate virus neutralization tests (sVNT) that are based on ELISA, and 233 measuring the competition of Ab and RBD for the binding to ACE, the cellular entry receptor 234 of the virus, did not find good agreement; this is inconvenient, as these assays could be 235 promising given that they have potential for large-scale.

In conclusion, the evaluated assays correlated well with each other but a difference in titers remained after adjustment to the same International Standard. Thus, the titer harmonization is not yet completely achieved, but it is better between assays detecting the same Ab against the same antigen than between assays with different targets.

240

## 241 Acknowledgements

242 This study was supported by Hospices Civils de Lyon and Fondation des Hospices Civils de

243 Lyon. The respective suppliers kindly provided all the serological kits used in this study.

244 We thank all the staff members of the occupational health and medicine department of the

245 Hospices Civils de Lyon who contributed to the sample collection. We thank all Clinical

255	References
254	
253	revision.
252	clinical study, and Philip Robinson for critical reading of the manuscript and language
251	automated platforms. Lastly, we thank all the healthcare workers for their participation in this
250	virology laboratory of the Hospices Civils de Lyon who performed the assays on the
249	(CRB HCL, Lyon France, Biobank BB-0033-00046). We thank all the technicians from the
248	de Lyon). Human biological samples and associated data were obtained from NeuroBioTec
247	of the clinical research and innovation department for their reactivity (DRCI, Hospices Civils
246	Research Associates, for their excellent work. We thank Karima Brahima and all the members

- Shi A. C., Ren P. SARS-CoV-2 Serology Testing: Progress and Challenges. 2021. J
   Immunol Methods 494 113060. https://doi.org/10.1016/j.jim.2021.113060
- 258 2. Bonelli F., Blocki F. A., Bunnell T., Chu E., De La O A., Grenache D. G., Marzucchi
- 259 G., Montomoli E., Okoye L., Pallavicini L., Streva V. A., Torelli A., Wagner A., Zanin
- 260 D., Zierold C., Wassenberg J. J. Evaluation of the Automated LIAISON® SARS-CoV-
- 261 2 TrimericS IgG Assay for the Detection of Circulating Antibodies. 2021. Clin Chem
- 262 Lab Med 59 (8) 1463–1467. <u>https://doi.org/10.1515/cclm-2021-0023</u>.
- 263 3. Bradley B. T., Bryan A., Fink S. L., Goecker E. A., Roychoudhury P., Huang M.-L.,
- 264 Zhu H., Chaudhary A., Madarampalli B., Lu J. Y. C., Strand K., Whimbey E., Bryson-
- 265 Cahn C., Schippers A., Mani N. S., Pepper G., Jerome K. R., Morishima C., Coombs R.
- 266 W., Wener M., Cohen S., Greninger A. L. Anti-SARS-CoV-2 Antibody Levels
- 267 Measured by the Advise Dx SARS-CoV-2 Assay Are Concordant with Previously
- 268 Available Serologic Assays but Are Not Fully Predictive of Sterilizing Immunity.
- 269 2021. J Clin Microbiol JCM0098921. https://doi.org/10.1128/JCM.00989-21.

270	4.	English E.,	Cook L. E.,	Piec I.	. Dervisevic S.	. Fraser W. D.	John W.	G. Performance of

- 271 the Abbott SARS-CoV-2 IgG II Quantitative Antibody Assay Including the New
- 272 Variants of Concern (VOC 202012/V1 (UK) and VOC 202012/V2 (South Africa)):
- 273 And First Steps towards Global Harmonization of COVID-19 Antibody Methods.
- 274 2021. J Clin Microbiol JCM0028821 <u>https://doi.org/10.1128/JCM.00288-21</u>.
- 5. Irsara C., Egger A. E., Prokop W., Nairz M., Loacker L., Sahanic S., Pizzini A.,
- 276 Sonnweber T., Holzer B., Mayer W., Schennach H., Loeffler-Ragg J., Bellmann-Weiler
- 277 R., Hartmann B., Tancevski I., Weiss G., Binder C. J., Anliker M., Griesmacher A.,
- 278 Hoermann G. Clinical Validation of the Siemens Quantitative SARS-CoV-2 Spike IgG
- 279 Assay (SCOVG) Reveals Improved Sensitivity and a Good Correlation with Virus
- 280 Neutralization Titers. 2021. Clin Chem Lab Med 59 (8) 1453–1462.
- 281 <u>https://doi.org/10.1515/cclm-2021-0214</u>.
- 282 6. Narasimhan M., Mahimainathan L., Araj E., Clark A. E., Markantonis J., Green A., Xu
- 283 J., SoRelle J. A., Alexis C., Fankhauser K., Parikh H., Wilkinson K., Reczek A.,
- 284 Kopplin N., Yekkaluri S., Balani J., Thomas A., Singal A. G., Sarode R., Muthukumar
- 285 A. Clinical Evaluation of the Abbott Alinity SARS-CoV-2 Spike-Specific Quantitative
- 286 IgG and IgM Assays among Infected Recovered and Vaccinated Groups. 2021. J Clin

287 Microbiol 59 (7) e0038821. <u>https://doi.org/10.1128/JCM.00388-21</u>.

- 288 7. Perkmann T., Perkmann-Nagele N., Koller T., Mucher P., Radakovics A., Marculescu
- 289 R., Wolzt M., Wagner O. F., Binder C. J., Haslacher H. Anti-Spike Protein Assays to
- 290 Determine SARS-CoV-2 Antibody Levels: A Head-to-Head Comparison of Five
- 291 Quantitative Assays. 2021. Microbiol Spectr 9 (1) e0024721.
- 292 https://doi.org/10.1128/Spectrum.00247-21.
- 293 8. Di Meo A, Miller JJ, Fabros A, Brinc D, Hall V, Pinzon N, Ierullo M, Ku T, Ferreira
- 294 VH, Kumar D, Pasic MD, Kulasingam V. 2021. Evaluation of Three anti-SARS-CoV-2

- 295 Serologic Immunoassays for Post-Vaccine Response. J Appl Lab Med.
- 296 <u>https://doi.org/10.1093/jalm/jfab087</u>.
- 297 9. Addetia A., Crawford K. H. D., Dingens A., Zhu H., Roychoudhury P., Huang M.-L.,
- 298 Jerome K. R., Bloom J. D., Greninger A. L. Neutralizing Antibodies Correlate with
- 299 Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a
- 300 High Attack Rate. 2020. J Clin Microbiol 58 (11) e02107-20.
- 301 <u>https://doi.org/10.1128/JCM.02107-20</u>.
- 302 10. Letizia A. G., Ge Y., Vangeti S., Goforth C., Weir D. L., Kuzmina N. A., Balinsky C.
- 303 A., Chen H. W., Ewing D., Soares-Schanoski A., George M.-C., Graham W. D., Jones
- 304 F., Bharaj P., Lizewski R. A., Lizewski S. E., Marayag J., Marjanovic N., Miller C. M.,
- 305 Mofsowitz S., Nair V. D., Nunez E., Parent D. M., Porter C. K., Santa Ana E.,
- 306 Schilling M., Stadlbauer D., Sugiharto V. A., Termini M., Sun P., Tracy R. P.,
- 307 Krammer F., Bukreyev A., Ramos I., Sealfon S. C. SARS-CoV-2 Seropositivity and
- 308 Subsequent Infection Risk in Healthy Young Adults: A Prospective Cohort Study.
- 309 2021. Lancet Respir Med 9 (7) 712–720.
- 310 https://doi.org/10.1016/S2213-2600(21)00158-2
- 311 11. McMahan K., Yu J., Mercado N. B., Loos C., Tostanoski L. H., Chandrashekar A., Liu
- 312 J., Peter L., Atyeo C., Zhu A., Bondzie E. A., Dagotto G., Gebre M. S., Jacob-Dolan
- 313 C., Li Z., Nampanya F., Patel S., Pessaint L., Van Ry A., Blade K., Yalley-Ogunro J.,
- 314 Cabus M., Brown R., Cook A., Teow E., Andersen H., Lewis M. G., Lauffenburger D.
- 315 A., Alter G., Barouch D. H. Correlates of Protection against SARS-CoV-2 in Rhesus
- 316 Macaques. 2021. Nature 590 (7847) 630–634.
- 317 https://doi.org/10.1038/s41586-020-03041-6
- 318 12. Rogers T. F., Zhao F., Huang D., Beutler N., Burns A., He W., Limbo O., Smith C.,
- 319 Song G., Woehl J., Yang L., Abbott R. K., Callaghan S., Garcia E., Hurtado J., Parren

320 M., Pen	g L., Ramirez S., Ricketts J.	, Ricciardi M. J., Rawlings S. A.,	Wu N. C., Yuan
-------------	-------------------------------	------------------------------------	----------------

- 321 M., Smith D. M., Nemazee D., Teijaro J. R., Voss J. E., Wilson I. A., Andrabi R.,
- 322 Briney B., Landais E., Sok D., Jardine J. G., Burton D. R. Isolation of Potent SARS-
- 323 CoV-2 Neutralizing Antibodies and Protection from Disease in a Small Animal Model.
- 324 2020. Science 369 (6506) 956–963. <u>https://doi.org/10.1126/science.abc7520</u>.
- 325 13. Mattiuzzo G., Bentley E. M., Hassall M., Routley S., Bernasconi V., Kristiansen P.,
- 326 Harvala H., Roberts D., Semple G., Turtle L. C., Openshaw P. J., Baillie K.,
- 327 Investigators C., Nissen-Meyer L. S. H., Brants A. B., Atkinson E., Rigsby P., Padley
- 328 D., Almond N., Rose N. J., Page M. 2020. Establishment of the WHO International
- 329 Standard and Reference Panel for Anti-SARS-CoV-2 Antibody. WHO/BS/2020.2403.
- 330 <u>https://www.who.int/publications/m/item/WHO-BS-2020.2403</u>
- 331 14. Bal A., Pozzetto B., Trabaud M.-A., Escuret V., Rabilloud M., Langlois-Jacques C.,
- 332 Paul A., Guibert N., D'Aubarède-Frieh C., Massardier-Pilonchery A., Fabien N.,
- 333 Goncalves D., Boibieux A., Morfin-Sherpa F., Pitiot V., Gueyffier F., Lina B., Fassier
- 334 J.-B., Trouillet-Assant S., COVID SER Study Group. Evaluation of High-Throughput
- 335 SARS-CoV-2 Serological Assays in a Longitudinal Cohort of Patients with Mild
- 336 COVID-19: Clinical Sensitivity Specificity and Association with Virus Neutralization
- 337 Test. 2021. Clin Chem 67 (5) 742–752. <u>https://doi.org/10.1093/clinchem/hvaa336</u>.
- 338 15. Kristiansen P. A., Page M., Bernasconi V., Mattiuzzo G., Dull P., Makar K., Plotkin S.,
- 339 Knezevic I. WHO International Standard for Anti-SARS-CoV-2 Immunoglobulin.
- 340 2021. The Lancet 397 (10282) 1347–1348. <u>https://doi.org/10.1016/S0140-</u>
- <u>6736(21)00527-4</u>.
- 342 16. Sholukh A. M., Fiore-Gartland A., Ford E. S., Miner M. D., Hou Y. J., Tse L. V.,
- 343 Kaiser H., Zhu H., Lu J., Madarampalli B., Park A., Lempp F. A., St. Germain R.,
- Bossard E. L., Kee J. J., Diem K., Stuart A. B., Rupert P. B., Brock C., Buerger M.,

- 345 Doll M. K., Randhawa A. K., Stamatatos L., Strong R. K., McLaughlin C., Huang M.-
- 346 L., Jerome K. R., Baric R. S., Montefiori D., Corey L. Evaluation of Cell-Based and
- 347 Surrogate SARS-CoV-2 Neutralization Assays. 2021. J Clin Microbiol. JCM0052721.
- 348 <u>https://doi.org/10.1128/JCM.00527-21</u>.
- 349
- 350

# **TABLE 1**: Performance of six commercial anti SARS-CoV-2 antibody assays.

Manufacturer	Wantai	Wantai	Siemens Healthineers	DiaSorin	bioMérieux	Abbott
platform			Atellica® IM	Liaison®	Vidas®	Architect
SARS-CoV-2 Detected Ab	Total Ab	IgG	IgG	IgG	IgG	IgG
Assay type	ELISA	ELISA	CLIA	CLIA	ELFA	CMIA
Antigen	RBD	RBD	RBD	Trimeric Spike	RBD	RBD
Positive threshold	Index = 1	U/mL = 0	U/mL = 1	AU/mL = 13	Index = 1	AU/mL = 50
Conversion factor (WHO standard)	N/A	N/A	21.8	2.6	20.33	0.142
Positive threshold (BAU/mL)	N/A	N/A	21.8	33.8	20.33	7.1
Sensitivity (%)	94.5	N/A	96.41	99	96.6	100
Specificity (%)	100	N/A	99.90	100	99.9	99.9
Positive samples, n (%)						
4 weeks after first injection (n=79)	68 (86.1%)	77 (97.5%)	74 (93.6%)	76 (96.1%)	75 (94.9%)	79 (100%)

4 weeks after						
full vaccination	94 (100%)	94 (100%)	94 (100%)	94 (100%)	94 (100%)	92/92 * (100%)
(n=94)						

353

- 354
- 355
- 356 Positivity was established according to manufacturers' instructions. Sensitivity and specificity
- 357 data were those described in the instruction for utilization sheet from each manufacturer.
- 358 Abbreviations: Ab: antibodies, Ig: immunoglobulin, ELISA: enzyme-linked immunosorbent

359 assay, CMIA: chemiluminescence microparticule immunoassay CLIA: chemiluminescence

360 immunoassay, ELFA: enzyme-linked fluorescent assay, N: number of samples, RBD:

- 361 Receptor Binding Domain, CI: confidence interval.
- 362 \* 2 samples did not remain in sufficient quantity to perform the Abbott assay
- 363

## 364 **TABLE 2:** Pearson correlation coefficient (ρ [IQR]) between each assay.

ASSAY	Abbott	bioMérieux	DiaSorin
Siemens	0.91 [0.89; 0.93]	0.85 [0.81; 0.88]	0.94 [0.92; 0.95]
DiaSorin	0.90 [0.87; 0.92]	0.86 [0.82; 0.89]	
bioMérieux	0.90 [0.87; 0.92]		

365	FIG 1: Comparison of anti SARS-CoV-2 antibodies concentration (BAU/mL) between all
366	assays in sera collected from vaccinated subjects. The statistical difference was evaluated by
367	Wilcoxon's test. Comparison of median titers between Siemens, DiaSorin, bioMérieux, and
368	Abbott assays. BAU/mL: Binding Antibodies Unit/mL. ****p<0.0001. Data from patients
369	scheduled to be vaccinated with 2 doses of Pfizer BioNtech vaccine (black) or with 1 dose of
370	AstraZeneca vaccine followed by 1 dose of Pfizer BioNtech (blue) are presented.

371

FIG 2: Passing and Bablok regression analyses using the Siemens, DiaSorin, bioMérieux, and
Abbott assays. A, The Siemens assay compared to the DiaSorin assay. B, bioMérieux
compared to DiaSorin. C, Abbott compared to DiaSorin. D, Siemens compared to
bioMérieux. E, Siemens compared to Abbott. F, Abbott compared to bioMérieux.

376

FIG 3: Bland-Altman plots comparing agreement between concentrations determined using
the Siemens, DiaSorin, bioMérieux, and Abbott assays. A, The Siemens assay compared to
the DiaSorin assay. B, bioMérieux compared to DiaSorin. C, Abbott compared to DiaSorin.
D, Siemens compared to bioMérieux. E, Siemens compared to Abbott. F, Abbott compared to
bioMérieux. The solid blue line represents the bias between assays, the dashed blue lines
represent 95%CI.

383





















